Načítá se...

Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer

Regorafenib, a novel multikinase inhibitor, has recently demonstrated overall survival benefits in metastatic colorectal cancer (CRC) patients. Our study aimed to gain further insight into the molecular mechanisms of regorafenib and to assess its potential in combination therapy. Regorafenib was tes...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Cancer
Hlavní autoři: Schmieder, Roberta, Hoffmann, Jens, Becker, Michael, Bhargava, Ajay, Müller, Tina, Kahmann, Nicole, Ellinghaus, Peter, Adams, Robert, Rosenthal, André, Thierauch, Karl-Heinz, Scholz, Arne, Wilhelm, Scott M, Zopf, Dieter
Médium: Artigo
Jazyk:Inglês
Vydáno: BlackWell Publishing Ltd 2014
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4277327/
https://ncbi.nlm.nih.gov/pubmed/24347491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.28669
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!